This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Health Winners & Losers: Genentech

Updated from 3:28 p.m. EDT

Health stocks nudged up slightly but then reversed in the second half of the day Wednesday, while analysts issued upgrades to some underpriced biotech and pharma stocks.

First, in potential biotech merger news, Genentech (DNA), which has been presented with an $89-a-share proposal from Swiss pharma company Roche, dipped into the $75 range midday Wednesday. This suggests investors are still concerned that Roche won't be able to arrange financing for the deal, despite the company's confidence. Shares did find some relief Wednesday, rallying to $80.56 before the close.

For reference, Genentech closed at $81.82 a share the last trading day before Roche announced its buyout proposal.

Meanwhile, ImClone (IMCL) shares were trading down 0.2% at $66.85 amid Eli Lilly's (LLY) proposed takeover for $70 a share -- an offer that's reportedly not subject to financing.

Both ImClone and Genentech are components of the Amex biotechnology index, which was up 1.19% midday only to reverse to a loss of 0.67% by the market's close.

Fellow component Celgene (CELG - Get Report) added $2.07, or 3.7%, to $57.95 Wednesday. Cowen and Co. analyst Rachel McMinn upgraded Celgene to outperform from neutral. McMinn said the current price doesn't fully account for the company's expected growth over the next few years.

In other news, Merrill Lynch upgraded Pfizer (PFE - Get Report) and Bristol-Myers Squibb (BMY) to underperform from buy. Pfizer was up 1.25% to $17.87 midday, only to settle into a loss of 2.9% later in the day. Bristol was up 3.13% to $19.43 in midday trading, but also settled back to a gain of just 0.5% at $18.94.

Also, Oppenhiemer initiated coverage on medical diagnostics company Myriad Genetics (MYGN - Get Report) with an outperform rating and a $92 price target. That stock added 4.7% at one point, but was trading up roughly 2.7% later in the day.

Elsewhere, Omrix Biopharmaceuticals (OMRI) shares tacked on 5.5% to $18.25 by midday, hanging on to a 3% gain later in the day. The company said that according to interim results from a midstage trial, its Fibrin Pad product was superior to Johnson & Johnson's (JNJ)Surgicel for stopping mild to moderate soft tissue bleeding during certain surgeries.

And, last, Dendreon (DNDN) shares continued to drop in the morning on higher than average volume for a second day after the Monday release of interim data on the company's prostate cancer vaccine Provenge. Dendreon's infamously volatile shares were down as much as 5% early Wednesday, but settled back to the flat line. The stock lost 15% the day prior after it gained 33% on Monday.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
IMCL $5.40 -3.57%
BMY $61.92 -0.61%
CELG $118.47 -1.53%
DNDN $0.06 -6.02%
MYGN $33.92 1.28%

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs